Endocrine Abstracts

Background and aim: Patients with GH deficiency (GHD) have increased risk of cerebrovascular events. The aim of this study was to evaluate the rate and factors associated with the occurrence of stroke, a major cause of death and disability, in adults with GHD.Patients and methods: Data from 15,188 GHD patients treated with GH replacement therapy (GHRT) enrolled in KIMS were analyzed. Stroke incidence rates were compared to rates from the Oxford Vascular ...

Background: The efficacy of recombinant human growth hormone replacement therapy (GHRT) has been demonstrated, in part, through clinical trials conducted worldwide. KIMS (Pfizer International Metabolic Database), established in 1994 and active until 2012, includes treatment outcome data and real world safety from 15 809 patients from 31 countries.Objective: The main objective of this analysis was to evaluate the long-term safety of patients with hypopitu...

Background: ACROSTUDY is an open-label, non-interventional post-authorization safety study that began in 2004 to evaluate safety in at least 1000 acromegaly patients treated with the GH receptor antagonist pegvisomant (PEGV). This commitment was fulfilled in Jan 2013. ACROSTUDY was later amended to enroll an additional 110 patients that were naïve/semi-naive to PEGV treatment. Semi-naïve patients are defined as not having received PEGV therapy for at least 6 months p...